Litigation Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

Docket		Date Filed	2017-01-13
Court	District Court, D. Delaware	Date Terminated	2017-02-24
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,148,359; 7,364,752; 8,025,899; 8,268,349; 8,309,613; 8,377,952; 8,399,015; 8,470,347; 8,691,878
Link to Docket	External link to docket

Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-13				External link to document
2017-01-12	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,148,359 C1; 7,364,752 C1; 8,025,899… 24 February 2017 1:17-cv-00047 830 Patent None District Court, D. Delaware	External link to document

AbbVie Inc. v. Aurobindo Pharma Limited, 1:17-cv-00047: Litigation Summary and Patent Analysis

Last updated: August 18, 2026

AbbVie Inc. v. Aurobindo Pharma Limited, No. 1:17-cv-00047, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Aurobindo's abbreviated new drug application for a generic version of Creon, AbbVie's delayed-release pancrelipase product. AbbVie asserted Creon formulation and drug-product patents after receiving Aurobindo's Paragraph IV certification. The case was resolved through a settlement and dismissal rather than a reported trial judgment on patent validity or infringement.

The dispute was commercially important because Creon generated substantial AbbVie revenue and generic pancrelipase products face technical manufacturing barriers involving enzyme potency, enteric protection, dissolution, stability, and batch uniformity.

What drug was involved in AbbVie v. Aurobindo?

The case involved Creon, a delayed-release oral formulation of pancrelipase used as pancreatic enzyme replacement therapy.

Field	Detail
Brand	Creon
Active ingredient	Pancrelipase
Dosage form	Delayed-release capsules
Manufacturer at filing	AbbVie Inc.
Regulatory pathway	ANDA
Generic applicant	Aurobindo Pharma Limited and related entities
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00047
Action type	Hatch-Waxman patent litigation
Filing period	January 2017
Resolution	Settlement and dismissal
Public merits judgment	None reported

Creon contains a mixture of digestive enzymes, including lipase, protease, and amylase. Its performance depends on release of enzymes in the small intestine rather than premature release in the stomach. That requirement creates formulation and manufacturing issues beyond ordinary small-molecule tablet replication.

What patents protected Creon in the Aurobindo litigation?

AbbVie asserted patents covering Creon-related pancrelipase formulations and drug products. Public patent records and FDA Orange Book data identify Creon patent protection in several patent families, including patents directed to enzyme compositions, delayed-release formulations, and product characteristics.

The key patent families associated with Creon litigation include the following:

Patent	General subject matter	Patent-term significance
U.S. Patent No. 8,574,827	Pancreatic enzyme and pancrelipase formulation technology	Earlier-generation formulation protection
U.S. Patent No. 9,669,014	Pancrelipase formulation and drug-product technology	Later-expiring formulation protection
Related Creon patents	Drug composition, release, stability, and manufacturing attributes	Potential follow-on barriers to generic entry

The asserted patent set should be distinguished from all patents listed for Creon. A patent may appear in the Orange Book without being asserted in every ANDA case. The operative pleadings and settlement record determine which patents were actually placed in dispute.

Creon protection was layered. AbbVie did not rely solely on a basic composition-of-matter patent. The relevant estate included patents directed to the final dosage form and performance characteristics. That structure is significant because a generic applicant may avoid one patent but still face infringement exposure under another formulation or product patent.

How did Aurobindo challenge AbbVie’s Creon patents?

Aurobindo's ANDA filing included Paragraph IV certifications challenging listed Creon patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

AbbVie's lawsuit triggered the Hatch-Waxman litigation framework:

1. Aurobindo submitted an ANDA to the FDA.
2. Aurobindo notified AbbVie of its Paragraph IV certifications.
3. AbbVie filed suit within the statutory 45-day period.
4. The lawsuit imposed an automatic 30-month stay on FDA approval, subject to statutory exceptions.
5. The parties resolved the action by settlement before a final merits determination.

The public docket does not establish a judicial finding that the asserted Creon patents were invalid or not infringed. A settlement and dismissal therefore should not be treated as a patent-validity decision.

What was the litigation timeline in 1:17-cv-00047?

Date or period	Event
January 2017	AbbVie filed the Delaware action against Aurobindo
2017	The case proceeded as an ANDA patent dispute involving Creon
2017-2019	Pleadings, discovery, and settlement negotiations continued
Settlement period	AbbVie and Aurobindo resolved the dispute without a reported trial decision
Post-settlement	The action was dismissed pursuant to the parties' agreement

The case belongs to a broader series of Creon patent actions brought by AbbVie against generic manufacturers. AbbVie separately litigated against other ANDA applicants, including companies seeking approval for generic delayed-release pancrelipase capsules.

Was there a Paragraph IV trial or judgment?

No reported final trial judgment resolved the central questions of Creon patent validity, infringement, or enforceability in this action.

The case ended through settlement. That means:

• There was no publicly reported claim-construction ruling establishing the controlling scope of the asserted claims.
• There was no final district-court determination that Aurobindo infringed.
• There was no final district-court determination that the patents were valid.
• There was no Federal Circuit merits opinion arising from the case.
• The settlement preserved commercial confidentiality over important launch and licensing terms.

A dismissal following settlement is procedurally different from a judgment after trial. It confirms that the parties resolved the dispute but does not disclose which side would have prevailed on the technical or legal merits.

When could Aurobindo launch a generic Creon product?

The settlement likely controlled Aurobindo's ability to market its generic product independently of the statutory 30-month stay. The public docket does not provide a judicially adjudicated launch date because the commercial terms of the settlement were not fully disclosed in the court's dismissal materials.

For commercial analysis, three dates must be separated:

Date type	Meaning
Patent expiration	The statutory end of a particular patent right
FDA approval date	The date on which FDA may approve the ANDA after resolving regulatory and patent barriers
Contractual launch date	The date permitted under a private settlement agreement

A settlement can authorize entry before the expiration of every listed patent, subject to agreed conditions. It can also impose restrictions unrelated to patent expiration, including delayed launch, supply arrangements, or covenants governing future litigation.

The case therefore should not be analyzed solely by calculating the latest Orange Book patent expiration. The settlement agreement is the controlling commercial document for Aurobindo's authorized entry rights.

What is the Orange Book status of Creon?

Creon is an FDA-approved prescription drug, and its listed patents have been used in the Hatch-Waxman framework for generic challenges. The Orange Book identifies patents and regulatory exclusivities submitted by the NDA holder for approved drug products.[1]

The Orange Book does not disclose every commercial term negotiated in patent settlements. It also does not independently establish whether a particular ANDA applicant has reached a settlement or obtained a license.

Relevant Orange Book issues include:

• Patent listings for delayed-release pancrelipase capsules.
• Product-specific patents covering different Creon strengths.
• Paragraph IV certifications submitted by generic applicants.
• The 30-month stay generated by timely patent litigation.
• Possible first-applicant exclusivity for a qualifying ANDA applicant.
• Patent delisting or expiration events affecting later generic approvals.

A generic applicant's FDA approval status must be evaluated separately from the existence of the Delaware lawsuit. Litigation resolution removes a patent dispute between the parties but does not itself guarantee FDA approval.

What formulation patents protect delayed-release pancrelipase?

Creon-type formulations are protected through technical characteristics that control enzyme release and performance.

Enteric protection

Pancreatic enzymes can be degraded or inactivated in the stomach. Delayed-release systems use coatings or other formulation techniques to protect enzyme particles until they reach a higher-pH environment in the small intestine.

Enzyme potency and composition

The drug product must deliver specified amounts of lipase, protease, and amylase. Patent claims may define enzyme ratios, activity ranges, particle characteristics, or compositional limits.

Dissolution and release profile

The product must satisfy dissolution behavior under specified test conditions. A formulation can be vulnerable to infringement claims if its release profile falls within the patent claims, even if the active ingredient is not itself patent-protected.

Stability and manufacturing controls

Enzyme products are sensitive to moisture, temperature, coating uniformity, and processing conditions. Manufacturing patents may cover methods for producing stable enzyme particles or achieving consistent enteric coating.

These technical elements create a higher barrier than ordinary immediate-release tablets. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence while controlling variability in enzyme activity and release.

How strong was AbbVie’s Creon patent estate?

AbbVie's Creon patent estate was stronger as a layered product estate than as a single blocking patent.

Strengths

• The patents addressed the finished dosage form rather than only pancrelipase as an active ingredient.
• The formulation required specialized enteric protection and enzyme-release performance.
• Multiple strengths and product configurations created potential claim-overlap issues.
• Manufacturing complexity increased the cost of designing around the patents.
• The product had substantial commercial value, giving AbbVie an incentive to litigate and negotiate.

Weaknesses

• Formulation patents are more exposed to obviousness and written-description challenges than classic composition-of-matter patents.
• Generic applicants can attempt design-around strategies using different coatings, excipients, particle sizes, or release specifications.
• Infringement may depend on confidential manufacturing parameters and testing results.
• A Paragraph IV challenger can attack claim construction, enablement, obviousness, and enforceability simultaneously.

The settlement prevented a public assessment of how the asserted claims would have performed under those challenges.

What generic entry risks existed for AbbVie?

The principal risk was erosion of Creon revenue through an FDA-approved generic delayed-release pancrelipase product.

Revenue exposure

Creon was a significant AbbVie product, particularly after AbbVie's acquisition of Allergan expanded its gastrointestinal portfolio. Creon revenue was exposed to:

• Direct substitution by generic pancrelipase capsules.
• Pharmacy benefit manager formulary pressure.
• Price reductions following multiple generic approvals.
• Product switching across dosage strengths.
• Hospital and specialty-pharmacy purchasing pressure.

The initial generic entrant would have had a stronger pricing position than later entrants. Multiple approved products would be expected to accelerate price erosion.

Technical entry barriers

The commercial threat was moderated by:

• Complex enzyme formulation requirements.
• Multiple dosage strengths.
• Delayed-release testing requirements.
• Manufacturing scale-up challenges.
• Need for consistent enzyme activity.
• Potential differences in labeling, capsule design, and administration instructions.

These barriers can delay commercial launch even after patent litigation is resolved.

Did biosimilar risk apply to Creon?

No. Creon is a chemically based pancrelipase drug product, not a biologic subject to the Biologics Price Competition and Innovation Act.

The relevant competitive pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The dispute therefore involved generic-drug patent litigation, not biosimilar interchangeability, reference-product exclusivity, or the abbreviated licensure pathway under section 351(k) of the Public Health Service Act.[2]

This distinction matters because:

• Aurobindo's application was an ANDA.
• Paragraph IV certifications, not a biosimilar patent dance, governed the dispute.
• FDA approval depended on pharmaceutical equivalence and bioequivalence requirements.
• No biosimilar interchangeability designation was relevant.

Did the case involve method-of-use patents?

The central dispute was product and formulation-focused. Creon treatment is associated with pancreatic enzyme replacement, including exocrine pancreatic insufficiency caused by conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic surgery.

Method-of-use patents can create additional Hatch-Waxman exposure when an ANDA applicant seeks approval for a patented indication. In the Creon litigation, the main commercial barriers were the drug product, delayed-release formulation, enzyme activity, and related manufacturing characteristics rather than a single use patent controlling the entire market.

FDA labeling carve-outs can sometimes reduce method-of-use exposure. They do not necessarily avoid infringement of product or formulation claims.

What was the settlement’s legal and commercial effect?

The settlement ended AbbVie's claims against Aurobindo without a public merits ruling. Its practical effects were:

• Aurobindo avoided the cost and risk of a full patent trial.
• AbbVie avoided an adverse validity or noninfringement judgment.
• The parties obtained contractual control over potential generic entry.
• The case no longer presented an immediate unresolved judicial challenge between AbbVie and Aurobindo.
• The settlement did not eliminate challenges by other generic applicants.
• The agreement did not determine the validity of Creon patents against nonparties.

Private Hatch-Waxman settlements can also raise antitrust and regulatory scrutiny, particularly where payment, delayed entry, or supply arrangements are involved. The court docket's dismissal does not by itself establish that the agreement contained a payment-for-delay provision. The Federal Trade Commission's pharmaceutical settlement reporting program is a separate source for reviewing reportable agreements.[3]

Which companies challenged Creon patents?

AbbVie brought multiple actions against generic applicants seeking approval for pancrelipase products. Aurobindo was one participant in a larger competitive field that included other major generic manufacturers.

The competitive landscape included:

• Aurobindo Pharma
• Viatris and Mylan-related entities
• Amneal Pharmaceuticals
• Other ANDA applicants pursuing delayed-release pancrelipase products

The number of litigants mattered because the first successful generic entrant could obtain a materially different commercial position from later entrants. A settlement with one applicant did not resolve the broader patent estate or prevent other companies from pursuing independent invalidity and noninfringement defenses.

How does Creon patent risk compare with ordinary generic drug risk?

Creon presented a more complex generic-entry profile than a conventional small-molecule tablet.

Risk factor	Ordinary tablet	Delayed-release pancrelipase
Active ingredient replication	Moderate	High
Enzyme potency control	Low relevance	High relevance
Enteric coating	Sometimes relevant	Central
Dissolution testing	Important	Highly product-defining
Manufacturing variability	Moderate	High
Formulation patent exposure	Moderate	High
FDA product-specific requirements	Moderate	High
Design-around feasibility	Often available	Technically difficult

The patent estate was not invulnerable. Formulation patents can be challenged. But the technical complexity increased the cost of an invalidity or noninfringement strategy and improved AbbVie's leverage in settlement negotiations.

What is the current litigation status of AbbVie v. Aurobindo?

The action was resolved and dismissed pursuant to settlement. It is not an active merits case requiring a pending trial or claim-construction analysis.

The case remains relevant for:

• Historical Creon patent strategy.
• Aurobindo's generic launch rights.
• Analysis of AbbVie's gastrointestinal-product exclusivity.
• Comparison with later Creon ANDA litigation.
• Evaluation of settlement-driven generic entry.
• Assessment of formulation and manufacturing patent risk.

The dismissal does not constitute a determination that the Creon patents were valid, enforceable, or infringed.

Key Takeaways

1. AbbVie v. Aurobindo, No. 1:17-cv-00047, was a Delaware Hatch-Waxman case involving Aurobindo's ANDA for generic Creon, a delayed-release pancrelipase product.
2. AbbVie relied on formulation, drug-product, and related manufacturing patent protection rather than a single active-ingredient patent.
3. Aurobindo's Paragraph IV challenge triggered the statutory patent-litigation framework and delayed FDA approval during the applicable stay period.
4. The parties settled and the case was dismissed without a reported trial judgment.
5. The settlement controlled Aurobindo's commercial entry rights, while its full terms were not publicly disclosed.
6. Biosimilar law was not relevant because Creon is a nonbiologic prescription drug.
7. Creon's technical formulation and manufacturing requirements created meaningful barriers beyond ordinary generic tablet development.
8. The case did not resolve the validity of AbbVie's Creon patents against other generic applicants.

FAQs

What was Aurobindo’s generic product in AbbVie v. Aurobindo?

Aurobindo sought FDA approval for a generic delayed-release pancrelipase product equivalent to Creon delayed-release capsules.

Did Aurobindo win the Creon patent case?

No court victory was entered for either side. The case ended through settlement and dismissal before a reported merits judgment.

Was Creon protected by a composition-of-matter patent?

The principal commercial protection involved pancrelipase drug-product and formulation technology, including delayed-release performance and related manufacturing characteristics.

Could Aurobindo launch before every Creon patent expired?

A settlement could authorize launch before expiration of all listed patents. The governing launch terms were contractual and were not fully disclosed in the public dismissal record.

Is generic pancrelipase subject to the biosimilar pathway?

No. Generic pancrelipase products proceed through the ANDA pathway, not the section 351(k) biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application ANDA process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. Federal Trade Commission. (2024). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov/legal-library/browse/competition-policy-guidance/agreements-filed-under-mma

4. U.S. District Court for the District of Delaware. (2017). AbbVie Inc. v. Aurobindo Pharma Limited, No. 1:17-cv-00047. Public docket.

5. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/